群英荟萃，智慧闪耀。肿瘤领域年度盛会2025美国临床肿瘤学会（ASCO）年会即将于2025年5月30日~6月3日在美国芝加哥举行。作为全球肿瘤学界的年度盛事，本届会议汇聚了大量具有突破性的研究成果。【肿瘤资讯】特别整理在研疗法中免疫治疗和靶向治疗两个专场的重磅研究，以飨读者。
在研疗法-免疫治疗
Developmental Therapeutics—Immunotherapy
Oral Abstract Session
摘要号：2500
报告人：张盼盼 北京大学肿瘤医院
英文标题：Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.
中文标题：评估LBL-024（一种针对PD-L1和4-1BB的新型双特异性抗体）联合依托泊苷/铂类化疗治疗未经治疗的晚期肺外神经内分泌癌（EP-NEC）的疗效：一项多中心Ib/II期试验
摘要号：2501
报告人：Timothy A. Yap, MD, PhD
The University of Texas MD Anderson Cancer Center
英文标题：First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.
中文标题：在CLDN6阳性晚期实体瘤患者中评估BNT 142（一种靶向Claudin 6（CLDN 6）和CD 3的首个mRNA编码双特异性抗体）的首次人体I/II期试验
摘要号：2502
报告人：郭军 北京大学肿瘤医院
英文标题：Efficacy and safety results of a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma.
中文标题：首创新药 PD-1/IL-2α-bias双特异性抗体融合蛋白 IBI363 治疗经免疫治疗的晚期肢端和黏膜黑色素瘤患者的疗效和安全性结果
摘要号：2503
报告人：Marina Baretti, MD
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
英文标题：A therapeutic vaccine for fibrolamellar hepatocellular carcinoma.
中文标题：一种针对纤维板层型肝细胞癌的治疗性疫苗
摘要号：2504
报告人：Ricky T Tong, MD, PhD
Main Line Health
英文标题：Clinical responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
中文标题：SYNC-T治疗的临床反应：转移性去势抵抗性前列腺癌（mCRPC）患者的原位个性化癌症疫苗接种联合瘤内免疫治疗
摘要号：2505
报告人：Hideto Ueki, MD, PhD
Kobe University
英文标题：Phase 1 study of B440, an oral Bifidobacterium-engineered WT1 cancer vaccine, in patients with metastatic urothelial cancer.
中文标题：B440（一种口服双歧杆菌工程WT1癌症疫苗）在转移性尿路上皮癌患者中的1期研究
摘要号：2506
报告人：Xiaoqian Nie 西湖大学
英文标题：Effect of erythrocyte-antibody conjugates on cancers resistant to checkpoint blockade immunotherapy: A phase I trial.
中文标题：红细胞抗体偶联物对检查点阻断免疫疗法耐药肿瘤的疗效：一项Ⅰ期试验
摘要号：2508
报告人：Martin Wermke
University Hospital Carl Gustav Carus
英文标题：Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
中文标题：IMA 203（一种靶向PRAME的自体TCR-T）在PD 1难治性转移性黑色素瘤患者中的1期临床研究更新
Clinical Science Symposium
摘要号：2509
报告人：Vanita Noronha, MD
Tata Memorial Hospital
英文标题：Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and beyond setting (DELII: Development of Low dose Immunotherapy in India).
中文标题：比较超低剂量免疫疗法与标准细胞毒性化疗用于实体瘤二线及以上治疗的III期随机研究（DELII：印度低剂量免疫疗法的开发）
摘要号：2510
报告人：Francis Albert Lévi, MD, PhD
UPR Chronotherapie, Cancers et Transplantation, Université Paris Saclay, Hôpital Paul Brousse ID Isco 13918
英文标题：Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: A bicentric bicontinental study.
中文标题：晚期非小细胞肺癌联合免疫化疗治疗时间与总生存期：一项双中心双大陆研究
摘要号：2511
报告人：Muntaser Al Zyoud, MD
University of Jordan
英文标题：Safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients: A systematic review and individual patient data meta-analysis.
中文标题：免疫检查点抑制剂在实体器官移植接受者中的安全性和有效性：一项系统性综述和个体患者数据荟萃分析
Rapid Oral Abstract Session
摘要号：LBA2512
报告人：Anna Maria Di Giacomo I, MD
University of Siena, Center for Immuno-Oncology, University Hospital of Siena, NIBIT Foundation Onlus
英文标题：The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.
中文标题：纳武利尤单抗+伊匹木单抗和ASTX 727或纳武利尤单抗+伊匹木单抗在PD-1耐药转移性黑色素瘤中的II期NIBIT-ML 1研究：肿瘤甲基化景观及其与临床结局的相关性
摘要号：2513
报告人：Anup Kasi, MD, MPH
University of Kansas Cancer Center
英文标题：Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
中文标题：ICI难治性或获得性耐药的持久反应：NP-G2-044联合抗PD-1治疗的2期研究
摘要号：2514
报告人：李志铭 中山大学肿瘤防治中心
英文标题：Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL).
中文标题：靶向CCR8抗体治疗复发/难治性皮肤T细胞淋巴瘤（R/R CTCL）的Ⅰ期临床试验剂量递增阶段初步结果
摘要号：2515
报告人：Judy S. Wang, MD
Florida Cancer Specialists & Research Institute
英文标题：An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors.
中文标题：SIRPα单克隆抗体BI 770371单独或与PD-1抑制剂ezabenlimab联合用于晚期实体瘤患者的开放标签I期试验
摘要号：2516
报告人：Kathryn Ries Tringale, MD, MS
UC San Diego
英文标题：A novel application of deep learning (DL)-based MRI with liquid biomarkers for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor (CAR) T-cell therapy.
中文标题：基于深度学习（DL）的MRI与液体生物标志物在嵌合抗原受体（CAR）T细胞治疗后免疫效应细胞相关神经毒性综合征（ICANS）中的新应用
摘要号：2517
报告人：Agrima Dutt, MS
New York University Grossman School of Medicine
英文标题：Role of autoimmune reactivity in neurotoxicities (N-Tox) in melanoma patients treated with immune-checkpoint inhibitors (ICI).
中文标题：自身免疫反应在接受免疫检查点抑制剂（ICI）治疗的黑色素瘤患者神经毒性（N-Tox）中的作用
摘要号：2518
报告人：Hirotaka Miyashita, MD
Dartmouth Cancer Center
英文标题：Natural killer cell transcriptomic expression and prediction of survival after immune checkpoint blockade across cancers.
中文标题：肿瘤免疫检查点阻断后自然杀伤细胞转录组表达和生存预测
摘要号：2519
报告人：Darwin Kwok, PhD, MS
University of California, San Francisco
英文标题：Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets.
中文标题：肿瘤宽RNA剪接畸变及其作为治疗新抗原靶点的潜力
摘要号：2520
报告人：Curtis J. Perry, MD, PhD
Yale School of Medicine
英文标题：Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas.
中文标题：默克尔细胞和小细胞肺癌患者肿瘤的扰动单细胞RNA测序
在研疗法-分子靶向药物和肿瘤生物学
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Oral Abstract Session
摘要号：3000
报告人：Aaron Elliott Lisberg, MD
UCLA Health Cancer Care, Thoracic Medical Oncology
英文标题：DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.
中文标题：DB-1310，一种HER 3靶向ADC，用于晚期实体瘤患者：1/2a期试验的初步结果
摘要号：3001
报告人：杨云鹏 中山大学肿瘤防治中心
英文标题：Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.
中文标题：EGFRxHER3 双特异性抗体药物偶联物iza-bren（BL-B01D1）治疗具有经典 EGFR 突变外的驱动基因改变（GA）的局部晚期或转移性非小细胞肺癌患者的Ⅰ期研究
摘要号：3002
报告人：黄岩 中山大学肿瘤防治中心
英文标题：Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).
中文标题：EGFRxHER3 双特异性抗体药物偶联物iza-bren（BL-B01D1）在局部晚期或转移性小细胞肺癌患者中的Ⅰ期研究
摘要号：3003
报告人：徐瑞华 中山大学肿瘤防治中心
英文标题：Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.
中文标题：新型双特异性抗HER2抗体-药物偶联物TQB2102在晚期实体瘤患者中的安全性和有效性：首次人体1期试验的初步数据
摘要号：3004
报告人：Jaume Capdevila, MD, PhD
Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology
英文标题：Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
中文标题：DLL3/CD3 T细胞接合器在DLL3高表达或低表达的肺外神经内分泌癌患者中的疗效和安全性：一项正在进行的I期试验的结果
摘要号：3005
报告人：Thorvardur Ragnar Halfdanarson, MD
Mayo Clinic Comprehensive Cancer Center
英文标题：[212Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.
中文标题：[212Pb]VMT-α-NET治疗表达生长抑素受体2（SSTR2）的神经内分泌肿瘤（NETs）：1年随访后的剂量限制毒性（DLT）观察参与者和扩展参与者的初步报告
摘要号：3006
报告人：Biswajit Das, PhD
Frederick National Laboratory for Cancer Research
英文标题：Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
中文标题：来自入选但不符合NCI-MATCH试验治疗组条件的不太常见癌症患者的匹配ctDNA和组织的全面基因组分析
摘要号：3007
报告人：Tadayoshi Hashimoto, MD, PhD
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East
英文标题：Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project.
中文标题：使用基于全基因组测序的个性化ctDNA panel进行超敏感泛癌分子残留疾病评估：MONSTAR-SCREEN-3项目的初步结果
摘要号：3008
报告人：Silver Alkhafaji, BS
University of California, San Francisco
英文标题：Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
中文标题：I-SPY2内分泌优化试验（EOP）中接受新辅助内分泌治疗（NET）的2/3期HR+HER2阴性癌症（BC）患者的循环肿瘤DNA（ctDNA）
Rapid Oral Abstract Session
摘要号：3009
报告人：Erika P. Hamilton, MD
Breast Cancer Research Program, Sarah Cannon Research Institute
英文标题：Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate.
中文标题：新型靶向B7-H4 dolasynthen抗体药物偶联物emiltatug ledadotin（Emi Le）的初始1期剂量递增数据
摘要号：3010
报告人：Kartik Sehgal, MD
Dana-Farber Cancer Institute
英文标题：Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).
中文标题：Sigvotatug vedotin（SV），一种靶向整合素β-6（IB 6）抗体药物偶联物（ADC）和帕博利珠单抗联合治疗：来自正在进行的I期研究（SGNB 6A-001）的初步结果
摘要号：3011
报告人：Kathryn C. Arbour, MD
Memorial Sloan Kettering Cancer Center
英文标题：BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.
中文标题：BMS-986504在伴有纯合MTAP缺失（MTAP-del）的晚期实体瘤患者中的应用：CA240-0007的临床更新和药代动力学（PK）和药效学（PD）分析的首次报告
摘要号：3012
报告人：Ecaterina Elena Dumbrava, MD
The University of Texas MD Anderson Cancer Center
英文标题：Preliminary results from a first-in-human, phase I/II study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced solid tumors.
中文标题：一项针对晚期实体瘤患者的口服KIF18A抑制剂VLS-1488的首次人体I/II期研究的初步结果
摘要号：3013
报告人：艾星浩 上海市胸科医院
英文标题：A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.
中文标题：GFH375（一种高选择性、强效口服 KRAS G12D 抑制剂）治疗 KRAS G12D 突变晚期实体瘤患者的首次人体Ⅰ/Ⅱ期研究
摘要号：3014
报告人：Alice P. Chen, MD
Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health
英文标题：Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study.
中文标题：selumetinib在1型神经纤维瘤病（NF 1）和有症状、不可手术的丛状神经纤维瘤（PN）成人中的疗效和安全性：KOMET（NCT 04924608）的主要分析，一项III期、国际、随机、安慰剂对照研究
摘要号：3015
报告人：Sarah Shin, MD, MPH
Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute
英文标题：Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1).
中文标题：尼洛替尼-紫杉醇联合治疗罕见实体瘤患者的2期评估：罕见肿瘤试验1（RARE CANCER 1）中联合抗肿瘤药物的快速分析和反应评估
摘要号：3016
报告人：Daniel Boon Yeow Chan, FRCP, MBBS, MRCP
ICON Cancer Centre
英文标题：Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.
中文标题：循环肿瘤RNA（ctRNA）在联合循环肿瘤DNA（ctDNA）和ctRNA下一代测序（NGS）泛癌液体活组织检查中的临床应用
摘要号：3017
报告人：Evelyn Ramberger, PhD
Aignostics GmbH
英文标题：Enhancing prognostic precision in bladder cancer: AI-driven tumor microenvironment analysis from H&E images.
中文标题：提高膀胱癌的预后精度：来自H&E图像的AI驱动的肿瘤微环境分析
排版编辑：肿瘤资讯-云初
本文专供医学专业人士参考，未经著作人许可，不可出版发行。同时，欢迎个人转发分享，其他任何媒体、网站如需转载或引用本网版权所有内容，须获得授权，且在醒目位置处注明“转自：良医汇-肿瘤医生APP”。
苏公网安备32059002004080号
